Cargando…

Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes

BACKGROUND: Hyperglycemia is associated with increased risk of all-site cancer that may be mediated through activation of the renin-angiotensin-system (RAS) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase (HMGCR) pathways. We examined the joint associations of optimal glycemic control (HbA(1c)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Alice PS, Yang, Xilin, So, Wing-Yee, Luk, Andrea, Ma, Ronald CW, Ozaki, Risa, Cheung, Kitty KT, Lee, Heung-Man, Yu, Linda, Xu, Gang, Chow, Chun-Chung, Chan, Juliana CN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046510/ https://www.ncbi.nlm.nih.gov/pubmed/24886453 http://dx.doi.org/10.1186/1741-7015-12-76

Ejemplares similares

Validation of Methods to Control for Immortal Time Bias in a Pharmacoepidemiologic Analysis of Renin–Angiotensin System Inhibitors in Type 2 Diabetes
por: Yang, Xilin, et al.
Publicado: (2014)

Additive Interaction Between the Renin-Angiotensin System and Lipid Metabolism for Cancer in Type 2 Diabetes
por: Yang, Xilin, et al.
Publicado: (2009)

Hypoglycaemia, chronic kidney disease and death in type 2 diabetes: the Hong Kong diabetes registry
por: Kong, Alice PS, et al.
Publicado: (2014)

Association between educational level and cardiovascular disease and all-cause mortality in patients with type 2 diabetes: a prospective study in the Joint Asia Diabetes Evaluation Program
por: Wu, Hongjiang, et al.
Publicado: (2018)

Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes: The Hong Kong Diabetes Registry
por: Yang, Xilin, et al.
Publicado: (2011)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Effects of Statins on Renin–Angiotensin System
por: Kiaie, Nasim, et al.
Publicado: (2021)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Evolution of Diabetes Care in Hong Kong: From the Hong Kong Diabetes Register to JADE-PEARL Program to RAMP and PEP Program
por: Ng, Ivy H.Y., et al.
Publicado: (2018)

Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study
por: Yang, Aimin, et al.
Publicado: (2022)

Low LDL Cholesterol, Albuminuria, and Statins for the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry
por: Yang, Xilin, et al.
Publicado: (2009)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Metabolic Syndrome Predicts New Onset of Chronic Kidney Disease in 5,829 Patients With Type 2 Diabetes: A 5-year prospective analysis of the Hong Kong Diabetes Registry
por: Luk, Andrea O.Y., et al.
Publicado: (2008)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study
por: Ting, Rose ZW, et al.
Publicado: (2010)

Association of Renin-Angiotensin System Blockers With Outcomes in Patients with COVID-19
por: Garg, Aakash, et al.
Publicado: (2020)

Association of Renin-Angiotensin System Blockers with Survival in Patients on Maintenance Hemodialysis
por: Kang, Seok Hui, et al.
Publicado: (2023)

Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?
por: Wiwanitkit, Viroj
Publicado: (2016)

Association of self-reported recurrent mild hypoglycemia with incident cardiovascular disease and all-cause mortality in patients with type 2 diabetes: Prospective analysis of the Joint Asia Diabetes Evaluation Registry
por: Luk, Andrea On Yan, et al.
Publicado: (2016)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
por: Heerspink, H. J. L., et al.
Publicado: (2016)

Renin-angiotensin system blockers regulate the metabolism of isolated fat cells in vitro
por: Caminhotto, R de O., et al.
Publicado: (2016)

Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2
por: Lévy, Bernard I., et al.
Publicado: (2020)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Impact of renin-angiotensin system inhibitors and beta-blockers on dental implant stability
por: Saravi, Babak, et al.
Publicado: (2021)

Impact of Renin‐Angiotensin System Blockers on Mortality in Veterans Undergoing Cardiac Surgery
por: Antoniak, Derrick T., et al.
Publicado: (2021)

Effect of renin-angiotensin system blocker on COVID-19 in young patients with hypertension
por: Kuzeytemiz, Mustafa, et al.
Publicado: (2022)

Genetic Variant of the Renin-Angiotensin System and Diabetes Influences Blood Pressure Response to Angiotensin Receptor Blockers
por: Konoshita, Tadashi, et al.
Publicado: (2009)

Additive Interaction of Hyperglycemia and Albuminuria on Risk of Ischemic Stroke in Type 2 Diabetes: Hong Kong Diabetes Registry
por: Yang, Xilin, et al.
Publicado: (2008)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

Reply to “Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?”
por: Fedson, David S., et al.
Publicado: (2016)

Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics
por: Gismondi, Ronaldo Altenburg, et al.
Publicado: (2015)

Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness
por: Kiuchi, Shunsuke, et al.
Publicado: (2015)

Angiotensin II Receptor Blocker Attenuates Intrarenal Renin-Angiotensin-System and Podocyte Injury in Rats with Myocardial Infarction
por: Wen, Zhu-zhi, et al.
Publicado: (2013)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
por: Genet, Bastien, et al.
Publicado: (2020)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7m26b4gg7rs5bnnrd8tt5g0a8i